RCS - hVIVO PLC - hVIVO launches unified brand identity

hVIVOAnnouncement

Today 07:02

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260414:nRSN2795Aa&default-theme=true

RNS Number : 2795A  hVIVO PLC  14 April 2026

 

hVIVO plc

("hVIVO", the "Company" or the "Group")

 

hVIVO launches unified brand identity reflecting strategic transformation into
integrated clinical development partner

 

Reinforces establishment of purpose-built, fully integrated platform, designed
to accelerate pathway to clinical proof-of-concept

 

London, UK - 14 April 2026, hVIVO plc (AIM: HVO), a purpose-built,
full-service international clinical development partner and the world leader
in human challenge trials, today announces the launch of a new brand identity,
reflecting the Group's strategic transformation from specialist provider to a
differentiated end-to-end drug development partner.

 

The rebrand follows the successful integration of Venn Life Sciences, CRS and
Cryostore and marks the completion of the Group's transition from a specialist
services provider to a fully integrated platform supporting clients from
preclinical strategy through to Phase II and selected Phase III programmes.
All operating companies will now trade under the hVIVO brand, simplifying the
Group's structure and re-enforcing its single partner model. This provides
clients with one integrated team, clear continuity across the development
pathway.

 

The Group now operates through four integrated service lines, forming a
purpose-built platform designed to generate faster, more decisive,
high-quality human data, reducing complexity, minimising handoffs and enabling
novel, more efficient trial designs:

·      Consulting: provides early stage scientific, regulatory and
development strategy support across the drug development lifecycle, enabling
clients to design robust programmes and generate decision ready data from the
outset. Drawing on deep expertise in early drug development, clinical
pharmacology and biostatistics, teams support sponsors from pre-clinical
planning through to clinical proof-of-concept, including study design, dose
rationale and regulatory strategy;

·      Clinical Trials: provides specialist early phase clinical trial
services through owned and controlled clinical research sites, supporting
studies from First-in-Human through to Phase II and selected Phase III
programmes. It includes full Phase I and II CRO services, complemented by
Phase II and III site services delivered within hVIVO's facilities. This model
enables greater operational control, accelerates timelines and ensures
reliable recruitment across healthy volunteers, patient populations and
specialist cohorts;

·      Human Challenge Trials: enables rapid and controlled evaluation
of vaccines and therapeutics by exposing healthy volunteers to well
characterised pathogens under carefully controlled conditions. These studies
allow earlier assessment of efficacy, biological response and dose selection
compared to traditional field-based studies;

·      Laboratories: provide specialist virology, immunology and
biomarker analysis to support early phase clinical development, human
challenge trials and standalone laboratory programmes. Closely integrated with
clinical operations, services include assay development, sample analysis and
data interpretation and biobanking with long-term storage capabilities.

 

Yamin 'Mo' Khan, Chief Executive Officer of hVIVO, said: "This rebrand
reflects our strategic transformation into a purpose-built, full-service
international clinical development partner, addressing the industry's need for
faster, high-quality data that can de-risk drug development.

 

"By bringing together consulting, clinical trials, human challenge trials and
laboratories into a single, unified platform, we offer clients a seamless
pathway from pre-clinical strategy to clinical proof-of-concept, delivered by
one expert partner. Our unified brand reinforces the strength of our
integrated model, proprietary infrastructure and deep scientific expertise,
and our ability to ultimately help pharmaceutical and biotech companies bring
important medicines to patients faster."

 

 

For further information please contact:

 

 hVIVO plc                                                                           +44 (0)20 7756 1300
 Yamin 'Mo' Khan, Chief Executive Officer

 Stephen Pinkerton, Chief Financial Officer

 Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)                                                      +44 (0)20 7220 0500
 Geoff Nash, Callum Davidson

Trisyia Jamaludin, Harriet Ward

 Nigel Birks - Life Science Specialist Sales

 Louise Talbot - Sales

 Peel Hunt LLP (Joint Broker)                                                                            +44 (0)20 7418 8900
 James Steel, Dr Christopher Golden

 Davy (Joint Broker)                                                                                     +353 (0) 1 679 6363
 Anthony Farrell, Niall Gilchrist

 ICR Healthcare (Financial PR & IR)                                                  hVIVO@icrhealthcare.com

 Mary-Jane Elliott / Stephanie Cuthbert / Phillip Marriage / Louis Ashe-Jepson

 

 

 

Notes to Editors

 

hVIVO plc (https://hvivo.com/) (AIM: HVO) is a purpose-built, full-service
international clinical development partner and the global leader in human
challenge trials, serving seven of the world's ten largest biopharma
companies.

 

The Company has an end-to-end platform designed to bring important medicines
to patients faster: spanning preclinical strategy, first‑in‑human studies,
Phase II patient trials and specialist laboratory services, delivered through
wholly owned sites and laboratories across the UK and Germany.

 

With a combined Group heritage of more than 100 years, hVIVO delivers an
accelerated pathway to clinical proof-of-concept through four integrated
service pillars: Consulting, Clinical Trials, Human Challenge Trials, and
Laboratories.

 

·    Consulting provides expert-led pre-clinical and clinical strategy,
encompassing non-clinical, clinical, CMC, pharmacokinetics, data management,
biostatistics, and regulatory support to guide trial design, execution, and
interpretation.

·    Clinical Trials offers Phase I/II CRO services, Phase II/III site
services across the UK and Germany, and specialist recruitment through
FluCamp, Europe's largest recruitment database.

·    Human Challenge Trials leverages hVIVO's state-of-the-art quarantine
facility in London - the largest of its kind worldwide - to deliver fast,
controlled, high-quality efficacy data through guaranteed viral exposure.

·    Laboratories provides cutting-edge virology and immunology
laboratory services, including biobanking and sample storage, supporting both
challenge trials and standalone client studies.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABIGDSBSBDGLX



            Copyright 2019 Regulatory News Service, all rights reserved